Paul W Stott

Does your pharmacy compound HDs? This insightful article by EQUASHIELD® shines light on USP <800> recommended safety guidelines. Read More: https://lnkd.in/eiUEgS7P #CSTD #hazardousdrugs

6

We conducted 𝟭𝟲 hours of 𝗾𝘂𝗮𝗹𝗶𝘁𝗮𝘁𝗶𝘃𝗲 interviews with HCPs and Senior Pharma industry leaders in the UK, supported by in-depth industry scanning. Our interviews reveal 𝗶𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝘁 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 about the 𝘁𝗲𝗻𝘀𝗶𝗼𝗻𝘀 𝗯𝗲𝘁𝘄𝗲𝗲𝗻 𝘄𝗵𝗮𝘁 𝗛𝗖𝗣𝘀 value versus what pharma delivers and the pandemic has 𝗯𝗿𝗼𝘂𝗴𝗵𝘁 𝘁𝗵𝗶𝘀 𝗶𝗻𝘁𝗼 𝘀𝗵𝗮𝗿𝗽 𝗳𝗼𝗰𝘂𝘀. 𝗥𝗲𝗮𝗱 𝗼𝘂𝗿 𝘄𝗵𝗶𝘁𝗲 𝗽𝗮𝗽𝗲𝗿 𝗵𝗲𝗿𝗲: https://lnkd.in/g8z3y-Um Get in touch to see how we can help - [email protected] - #pharma #pharmaceuticals #marketaccess #ICS #IntegratedCareSystem #ICB #HCPs

15

𝗥𝗲𝗮𝗱 𝗼𝘂𝗿 𝘄𝗵𝗶𝘁𝗲 𝗽𝗮𝗽𝗲𝗿 𝗵𝗲𝗿𝗲: https://lnkd.in/g8z3y-Um Get in touch to see how we can help - [email protected] - #pharma #pharmaceuticals #marketaccess #ICS #IntegratedCareSystem #ICB #HCPs

3

When manufacturing pharmaceuticals, there are often many complex steps to the process — each of which may require specialist machinery and an expert labour force to achieve. Steven Falcone, Senior Director of Compliance and External Engagement, Pharma Services, at Thermo Fisher Scientific discusses how CDMOs can assist #pharmaceutical companies in drug production, and how they can enhance supply chain efficiency. #pharmaceuticalmanufacturing #CDMO #drugproduction

1

📢 **VPAG Agreement: A New Era for Pharmaceutical Manufacturers in the UK?** The new VPAG agreement signals a significant shift in the UK pharmaceutical landscape, promising substantial NHS savings and increased investment in clinical trials. Noteworthy changes from the previous VPAS include innovative rebate structures and payment models, creating both opportunities for new medicines and hurdles for existing products. 🔑 **Key Actions:** - **Adapt Pricing Strategies**: Align pricing models with VPAG's revised rebate structures. - **Invest in Innovation**: Prioritize the development of new medications to leverage favorable terms for fresh products. - **Engage in Policy Dialogue**: Take part in policy discussions to shape forthcoming adjustments. - **Monitor Market Trends**: Stay updated on market shifts and tailor market access strategies accordingly. Exciting times lie ahead for pharmaceutical manufacturers in the UK as they navigate the evolving landscape shaped by the VPAG agreement. Are you ready to seize the opportunities and tackle the challenges this new era presents? #Pharmaceuticals #UKHealthcare #VPAGAgreement #MarketAccess Please note all views and content stated here are my own

16

Our most forward thinking clients have adopted this approach and are making much smarter investment decisions as well as identifying significant gaps with the time available to address them before they turn into significant issues! Contact us if you’d like to understand more about our innovative approaches to early commercialisation!

3

The Top Ten Branded searches on the WaveData Live system are an interesting indicator of the focus areas for key players in the UK Pharma sector. Here's the countdown for July 2024........ You can see the Top Ten Brand searches, alongside other industry insights in the latest WaveData Bulletin. www.wavedata.co.uk/kb #pharmapricing #pharmatopten #wavedatabulletin

7

🚨 Alert: to all my compliance connections working in the life sciences industry! 📝 Did you know... ...that The Association of the British Pharmaceutical Industry (ABPI) and the Prescription Medicines Code of Practice Authority (PMCPA) have just released an updated Code of Practice for the pharmaceutical industry. This 2024 update sets even higher standards for ethical conduct, transparency, and professionalism, ensuring the industry continues to operate with the utmost integrity. Do you want to stay abreast of the constant evolving landscape of compliance in the life sciences industry? Than contact the compliance specialists at GCO Global today for our (permanent or on-demand) compliance solutions. Contact Marlize Eckert, Yana Budel or Andreea Crăcuț to learn more about their expertise and industry knowledge and how you can gain the leverage! #lifesciences #compliance #stakeholderengagement #biotech

7

New #PharmlandPodcast episode just dropped 🚨 https://rxbene.fit/4etXOda Hosts J Bradley Nelson and Thomas Davies unpack the factors driving prescription costs at the #pharmacy counter, from the role of high-deductible plans to #formulary tiers and #PBM dynamics. These unseen cost drivers aren’t just numbers – they impact members’ access and decision-making. Tune in to better understand what goes into the pricing and how members can manage what they pay at the counter.

26

*GSK sells off remaining stake in Haleon* Sale of 4.2% holding raises £1.25bn for pharmaceutical group as it shifts focus to high-value drugs GSK has sold its remaining stake in Haleon, the consumer healthcare company it spun off and listed in London in July 2022, raising £1.25bn and underscoring how pharmaceutical groups are streamlining their businesses to focus on high-value drugs. The sale of the 4.2 per cent stake marks the end of the FTSE 100 company’s links to the maker of Panadol painkillers and Sensodyne toothpaste. GSK on Friday said it had sold more than 385mn shares at 324p a share, representing a 2.6 per cent discount to its closing price of 332.4p on Thursday. The British pharmaceutical company’s exit from Haleon was anticipated. The group had made three previous stock disposals since May 2023, when it held 12.9 per cent of the spin-off’s shares. The company said its exit was “consistent with its previous commitments to monetise its holding in a disciplined manner.” In total, stock disposals over the past year have helped GSK raise just under £4bn, which can be redirected to reducing debt or for mergers and acquisitions. Haleon was formed in 2019 as a joint venture of Pfizer and GSK’s consumer health assets. The decision to list the division in 2022 marked the largest public offering in London in a decade. It came after years of pressure from shareholders, with activist investor Elliott Advisors building a stake in the UK drugmaker and pushing GSK to speed up the process. https://lnkd.in/du4hdZg3

1

The Top Ten Branded searches on the WaveData Live system are an interesting indicator of the focus areas for key players in the UK Pharma sector. Here's the countdown for April 2024........ You can see the Top Ten Brand searches, alongside other industry insights in the latest WaveData Bulletin. www.wavedata.co.uk/kb #pharmapricing #pharmatopten #wavedatabulletin

7

Boost your knowledge on sleep and stress with this essential guide for #pharmacists! Learn how to support your customers with expert advice and OTC recommendations. Click on the link below to complete the module today: https://lnkd.in/ecjPuHCU

8

~~~Let these stats* sink in...~~~ UK pharma - we have problems. (see comments for proposed PMCPA solutions and our suggestions). 🛑 How long does it take for #pharma materials to potentially harm patients? - Not long & CONTENT was one of the biggest causes of #ABPICode breaches in 2024. 📆 How long does a promotional campaign last? - Not long so breaches apply to "legacy materials" and mistakes are blamed on the past. 😐 "I will have left this job by the time the #PMCPA rule - I won't care" - If the care is not there, nor will there be compliance. *Data based on cases published Jan-Oct 2024 #compliance #transparency #selfregulation

27

14 Comments

The Top Ten Branded searches on the WaveData Live system are an interesting indicator of the focus areas for key players in the UK Pharma sector. Here's the countdown for May 2024........ You can see the Top Ten Brand searches, alongside other industry insights in the latest WaveData Bulletin. www.wavedata.co.uk/kb #pharmapricing #pharmatopten #wavedatabulletin

1

The Top Ten Branded searches on the WaveData Live system are an interesting indicator of the focus areas for key players in the UK Pharma sector. Here's the countdown for August 2024........ You can see the Top Ten Brand searches, alongside other industry insights in the latest WaveData Bulletin. www.wavedata.co.uk/kb #pharmapricing #pharmatopten #wavedatabulletin

3

Too Many Cooks Spoil the Broth..... When managing the complex processes of pharmaceutical production, involving multiple partners can often lead to inefficiencies, increased costs, and challenges in maintaining communication. At Surepharm Services Ltd, we are a cost-effective UK-based CDMO with over 30 years of expertise in oral dose human and veterinary medicines. Our full licenses from the VMD and MHRA, combined with our GMP accreditation, enables us to offer an end-to-end solution for manufacturing, assembly/packing, and testing/release of product to market —all under one roof. If you hope to streamline operations, get to market quicker, reduce cost or increase consistent quality in 2025, pop us a message and lets chat. #Pharma #Biotech #Human #Animal #Oralsoliddose #Manufacturing #Production #assembly #packing #testing #release #VMD #HMRA #GMP

12